Scenic Biotech B.V., founded in 2017 and headquartered in Amsterdam, Netherlands, specializes in developing genomics and immunotherapy technologies aimed at addressing cancer and rare genetic diseases at the genetic level. The company focuses on identifying and harnessing disease suppressing genes, which serve as potential drug targets. By creating innovative therapies that target these genetic suppressors, Scenic Biotech aims to unlock new treatment possibilities for patients suffering from severe diseases.
Memo Therapeutics AG, based in Basel, Switzerland, specializes in antibody discovery and immune repertoire analysis through its innovative MemoMAB platform. This technology enables the creation of a recombinant in vitro copy of an individual’s B cell and antibody repertoire, resulting in unique and extensive libraries that reflect a person's immune response. These libraries are anticipated to contain a significant number of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics employs its MemoMAB platform in proprietary antibody lead discovery programs and offers it for collaboration with other entities, enhancing the potential for novel therapeutic developments.
Rejuvenate Biomed is a biomedical company researching the biology of aging & applying this knowledge to identify safe and well tolerated drugs to maintain and restore our natural cell resilience capacity improving the respons to age-related diseases.
Caresyntax Inc. develops a technology platform specializing in surgical analytics to enhance safety and efficiency in hospitals and ambulatory surgical centers. The company offers solutions designed to identify and manage risks, automate workflows, and reduce variability in surgical procedures. Its flagship products include qvident, a performance management software that enables surgical teams to create and share surgical content, and PRIME365, an integration platform that consolidates key surgical data from various sources such as video, audio, patient vitals, and procedural timestamps. Caresyntax's offerings support a range of surgical procedures, from minimally invasive to robotic surgeries, and can be deployed as HIPAA-compliant software through on-premise, cloud-based, or hybrid installations. Established in 1991, Caresyntax is headquartered in Boston, Massachusetts.
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, that specializes in developing nanoparticle-based therapeutics aimed at treating autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. Topas has a clinical-stage pipeline that includes its lead product candidate, TPM203, which is currently being tested for pemphigus vulgaris, along with other programs targeting conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research partnerships with major pharmaceutical firms, including Eli Lilly and Boehringer Ingelheim, to advance its mission of addressing significant unmet medical needs.
Caresyntax Inc. develops a technology platform specializing in surgical analytics to enhance safety and efficiency in hospitals and ambulatory surgical centers. The company offers solutions designed to identify and manage risks, automate workflows, and reduce variability in surgical procedures. Its flagship products include qvident, a performance management software that enables surgical teams to create and share surgical content, and PRIME365, an integration platform that consolidates key surgical data from various sources such as video, audio, patient vitals, and procedural timestamps. Caresyntax's offerings support a range of surgical procedures, from minimally invasive to robotic surgeries, and can be deployed as HIPAA-compliant software through on-premise, cloud-based, or hybrid installations. Established in 1991, Caresyntax is headquartered in Boston, Massachusetts.
Rejuvenate Biomed is a biomedical company researching the biology of aging & applying this knowledge to identify safe and well tolerated drugs to maintain and restore our natural cell resilience capacity improving the respons to age-related diseases.
SWORD Health Lda. is a digital healthcare provider specializing in the treatment of musculoskeletal disorders through technology-driven solutions. Founded in 2012 and headquartered in Porto, Portugal, the company enables patients to undertake therapy in the comfort of their homes, effectively addressing chronic and post-surgical pain without the need for imaging, surgeries, or opioids. Since its launch in 2015, SWORD Health has partnered with insurers, health systems, and employers across Europe, Australia, and the United States, making its services accessible to a broad audience. The company combines the expertise of licensed physical therapists with innovative technology to deliver effective rehabilitation, aiming to alleviate pain for millions of people globally. SWORD Health maintains offices in New York City, Chicago, Salt Lake City, Sydney, and Porto.
CatalYm GmbH, founded in 2016 and based in Munich, Germany, specializes in the development of immuno-oncology therapeutics. The company focuses on creating antibodies that target a placental factor known to be overexpressed in various tumor types. Through its innovative approach, CatalYm aims to enhance cancer treatment options and improve patient outcomes in the field of oncology.
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, that specializes in developing nanoparticle-based therapeutics aimed at treating autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. Topas has a clinical-stage pipeline that includes its lead product candidate, TPM203, which is currently being tested for pemphigus vulgaris, along with other programs targeting conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research partnerships with major pharmaceutical firms, including Eli Lilly and Boehringer Ingelheim, to advance its mission of addressing significant unmet medical needs.
SWORD Health Lda. is a digital healthcare provider specializing in the treatment of musculoskeletal disorders through technology-driven solutions. Founded in 2012 and headquartered in Porto, Portugal, the company enables patients to undertake therapy in the comfort of their homes, effectively addressing chronic and post-surgical pain without the need for imaging, surgeries, or opioids. Since its launch in 2015, SWORD Health has partnered with insurers, health systems, and employers across Europe, Australia, and the United States, making its services accessible to a broad audience. The company combines the expertise of licensed physical therapists with innovative technology to deliver effective rehabilitation, aiming to alleviate pain for millions of people globally. SWORD Health maintains offices in New York City, Chicago, Salt Lake City, Sydney, and Porto.
OncoDNA, with over 60 years’ expertise in medical diagnostics, was founded by a team of experts with many years of experience in DNA sequencing and diagnostic analyses in oncology.
Mecuris is a company based in Munich, Germany, that specializes in the development of custom-made orthopedic solutions, including orthoses and prostheses. Founded in 2016, Mecuris aims to enhance the lives of wearers by enabling orthopedic professionals to co-create personalized products through its innovative Mecuris Solution Platform. This platform leverages patient data and scans to semi-automatically generate individualized 3D designs, which are then prepared for printing at local 3D printing hubs. By streamlining the design and manufacturing process, Mecuris significantly reduces production times by 75%, allowing for a completely customized fit and functionality tailored to each user. The company’s digital approach and expertise in 3D printing position it as a key player in the orthopedic and prosthetic industry, facilitating rapid delivery of bespoke solutions.
Tonic App S.A. is a digital health company that has developed a mobile application aimed at enhancing communication and collaboration among medical professionals. The application serves as a comprehensive platform for doctors to message, share, and archive patient cases, request expert advice, and network with peers. It also enables hospitals, pharmaceutical companies, and medical associations to connect with healthcare professionals and disseminate relevant medical content. Key features of the app include tools for coordinating urgent procedures, discussing clinical cases, sharing medical images, and accessing a range of healthcare resources, such as clinical calculators and drug conversion tables. Founded in 2016 and headquartered in Porto, Portugal, Tonic App strives to improve the efficiency of medical practice and patient outcomes through its integrated approach to health content aggregation and team collaboration. The application is available on Google Play.
Forendo Pharma is a drug discovery and development company based in Turku, Finland, established in 2013. The company specializes in creating novel therapies for urological and endocrinological diseases, focusing on tissue-specific regulation of sex hormone mechanisms. Its primary product, Fispemifene, is a selective estrogen receptor modulator designed to address the symptoms of low testosterone in men. Additionally, Forendo Pharma is developing a 17HSD1-inhibitor targeting endometriosis, which aims to meet unmet medical needs in both women's and men's health. Through its innovative approach, Forendo Pharma seeks to enhance treatment options for a range of gynecological and urological conditions.
DEARhealth, Inc. operates as a health technology company which designs and develops SaaS based health care management platform for medical providers and health insurers. The company uses advanced data analytics to drive disease-specific, coordinated care pathways with streamlined provider workflows, patient apps, and organizational decision support. The company was founded in 2013 and is based in Beverly Hills, California.
Mecuris is a company based in Munich, Germany, that specializes in the development of custom-made orthopedic solutions, including orthoses and prostheses. Founded in 2016, Mecuris aims to enhance the lives of wearers by enabling orthopedic professionals to co-create personalized products through its innovative Mecuris Solution Platform. This platform leverages patient data and scans to semi-automatically generate individualized 3D designs, which are then prepared for printing at local 3D printing hubs. By streamlining the design and manufacturing process, Mecuris significantly reduces production times by 75%, allowing for a completely customized fit and functionality tailored to each user. The company’s digital approach and expertise in 3D printing position it as a key player in the orthopedic and prosthetic industry, facilitating rapid delivery of bespoke solutions.
OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activate an endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.
Forendo Pharma is a drug discovery and development company based in Turku, Finland, established in 2013. The company specializes in creating novel therapies for urological and endocrinological diseases, focusing on tissue-specific regulation of sex hormone mechanisms. Its primary product, Fispemifene, is a selective estrogen receptor modulator designed to address the symptoms of low testosterone in men. Additionally, Forendo Pharma is developing a 17HSD1-inhibitor targeting endometriosis, which aims to meet unmet medical needs in both women's and men's health. Through its innovative approach, Forendo Pharma seeks to enhance treatment options for a range of gynecological and urological conditions.
SWORD Health Lda. is a digital healthcare provider specializing in the treatment of musculoskeletal disorders through technology-driven solutions. Founded in 2012 and headquartered in Porto, Portugal, the company enables patients to undertake therapy in the comfort of their homes, effectively addressing chronic and post-surgical pain without the need for imaging, surgeries, or opioids. Since its launch in 2015, SWORD Health has partnered with insurers, health systems, and employers across Europe, Australia, and the United States, making its services accessible to a broad audience. The company combines the expertise of licensed physical therapists with innovative technology to deliver effective rehabilitation, aiming to alleviate pain for millions of people globally. SWORD Health maintains offices in New York City, Chicago, Salt Lake City, Sydney, and Porto.
Ncardia BV is a biotechnology company based in Leiden, the Netherlands, that specializes in developing and manufacturing human induced pluripotent stem cell-based solutions for drug discovery and cell therapy. Established in 2017, the company focuses on expediting the drug discovery and development process by utilizing high-quality iPSC technology. Ncardia's offerings include disease modeling, assay development, large-scale iPSC manufacturing, and iPSC-based screening. These capabilities enable researchers to conduct predictive human cellular assays for safety and efficacy testing of drug candidates, specifically enhancing cardiovascular and neural drug screening. Through its innovative approaches, Ncardia aims to provide valuable insights into human disease biology, thereby accelerating the overall drug discovery process.
OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activate an endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.
Exact Imaging develops high-resolution micro-ultrasound systems for enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Its micro-ultrasound system enables visualization and targeting of suspicious regions, in addition to performing systematic TRUS biopsies for prostate cancer imaging and the surrounding anatomy. The company also offers FusionVu micro-ultrasound/MRI fusion application to complement its ExactVu micro-ultrasound system for prostate imaging and biopsy. Exact Imaging was formerly known as Imagistx, Inc. and changed its name to Exact Imaging in March 2015. The company was founded in 2003 and is based in Markham, Canada.
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.
Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.
Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):
Ogeda SA, a clinical-stage drug discovery company, invents and develops small molecule drugs targeting G-Protein Coupled Receptors. It offers fezolinetant (ESN364), a Phase II clinical development product for the treatment of women’s health disorders; NK3 antagonists for the treatment of hormone-dependent pathologies in women's health; and products for endocrine, CNS/inflammatory disorders. Ogeda SA was formerly known as Euroscreen SA and changed its name to Ogeda SA in October 2016. The company was founded in 1994 and is based in Gosselies, Belgium. It has a meeting facility in Brussels, Belgium; and an additional office in Paris, France. Ogeda SA operates as a subsidiary of Astellas Pharma Inc.
Apitope is a biotech company focused on the discovery and development of disease modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, Factor VIII intolerance and uveitis. The company, whose first product candidate is licensed to Merck Serono, will now progress its remaining portfolio of product candidates developed with its proprietary platform technology.
OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activate an endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.
Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
Humedics GmbH, founded in 2009 and based in Berlin, Germany, specializes in the development of a breath analysis device designed to assess liver function in patients suffering from liver failure. The company's key product, the LiMAx test, is a diagnostic system that includes a medical device, breath masks, and a diagnostic drug, enabling clinicians to quantitatively evaluate individual liver function. This technology supports various applications, such as assessing liver function before and after transplantation, planning liver surgeries, and evaluating conditions like liver cirrhosis. By providing rapid and precise measurements at the bedside, LiMAx facilitates informed decision-making for tailored medical treatments, thereby enhancing patient outcomes. The company has successfully used its technology with thousands of patients and is focused on expanding its global operations.
Ncardia BV is a biotechnology company based in Leiden, the Netherlands, that specializes in developing and manufacturing human induced pluripotent stem cell-based solutions for drug discovery and cell therapy. Established in 2017, the company focuses on expediting the drug discovery and development process by utilizing high-quality iPSC technology. Ncardia's offerings include disease modeling, assay development, large-scale iPSC manufacturing, and iPSC-based screening. These capabilities enable researchers to conduct predictive human cellular assays for safety and efficacy testing of drug candidates, specifically enhancing cardiovascular and neural drug screening. Through its innovative approaches, Ncardia aims to provide valuable insights into human disease biology, thereby accelerating the overall drug discovery process.
Trod Medical S.A. is a medical equipment and surgical device manufacturer founded in 2006, with headquarters in Leuven, Belgium, and a presence in the Tampa Bay area, USA. The company specializes in developing innovative ablation technologies, particularly focusing on radiofrequency (RF) ablation devices. Trod Medical's flagship product, the EncageTM, is a disruptive percutaneous RF device that enables precise tissue ablation, significantly reducing collateral damage—a critical concern in treatments for conditions such as prostate cancer. With prostate cancer being one of the most prevalent cancers, affecting approximately 240,000 new patients annually in the United States, Trod Medical's technology addresses the limitations of conventional treatments that often lead to severe side effects, including erectile dysfunction and urinary incontinence. The company aims to enhance patient outcomes through its advanced medical devices designed for the focal ablation of soft tissues.
Complix NV is a biopharmaceutical company based in Diepenbeek, Belgium, with research facilities in Zwijnaarde, Belgium, and an office in Esch-sur-Alzette, Luxembourg. Founded in 2008, the company specializes in the discovery and development of Alphabodies, a novel class of protein therapeutics designed to target difficult disease sites, particularly in oncology and autoimmune diseases. These Alphabodies demonstrate high affinity for a variety of disease targets and possess unique stability and versatility, enabling non-injectable delivery methods. Complix aims to address challenging intracellular targets, thereby offering patients alternatives to traditional antibodies and small molecules, with the intent of improving treatment outcomes for complex conditions such as cancer, autoimmune disorders, and viral diseases.
FF Pharmaceuticals BV is a biopharmaceutical company based in Utrecht, the Netherlands, specializing in the development of disease-modifying therapeutics for inflammatory and autoimmune diseases. The company focuses on an anti-CD40 monoclonal antibody therapy designed to treat chronic inflammatory conditions such as primary biliary cirrhosis and Crohn's disease. This therapy acts as a negative allosteric modulator of the CD40 pathway, functioning as a reversible switch for B cell activation and inhibiting immune responses. By targeting the CD40 pathway, FF Pharmaceuticals aims to address the underlying immune dysregulation associated with these diseases, offering potential new treatment options for patients.
Private Equity Round in 2012
Ogeda SA, a clinical-stage drug discovery company, invents and develops small molecule drugs targeting G-Protein Coupled Receptors. It offers fezolinetant (ESN364), a Phase II clinical development product for the treatment of women’s health disorders; NK3 antagonists for the treatment of hormone-dependent pathologies in women's health; and products for endocrine, CNS/inflammatory disorders. Ogeda SA was formerly known as Euroscreen SA and changed its name to Ogeda SA in October 2016. The company was founded in 1994 and is based in Gosselies, Belgium. It has a meeting facility in Brussels, Belgium; and an additional office in Paris, France. Ogeda SA operates as a subsidiary of Astellas Pharma Inc.
Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
Trinean is a Belgium based technology provider, bringing micro-volume molecular spectroscopy to the next level by combining best in class analytical software with a highly standardized read-out platform. Founded in 2006 as a spin-out of the Ghent University, Belgium and Imec Leuven, Belgium, the company commercializes UV/VIS spectrometers for biomolecule quantification. The DropSense™16 and DropSense™96, analyzing up to 16 and 96 samples resp., use microfluidic chips for standardized sample analysis (DropPlates™ and Slides). The Trinean platform is complemented with a software toolbox for improved data interpretation and lab-automation.
Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. Amakem's product pipeline is based on its unique ‘Localized Drug Action' platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.
ProFibrix B.V., a biotech company, creates, develops, and markets products for the hemostasis and regenerative medicine markets. Its products include Fibrocaps, a dry powder topical hemostat and tissue sealant based on a mixture of fibrinogen and thrombin, which stops acute and severe bleeding during surgery or in connection with trauma injury. The company also provides a sterilized single-use delivery device to deliver Fibrocaps to the target tissue area without the need to manipulate the wound in a surgical environment. It offers its products based on human fibrinogen, a natural blood protein for haemostasis, blood clotting, and tissue repair and healing. ProFibrix B.V. was founded in 2004
Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
Activaero GmbH, a drug delivery company, engages in the research, development, manufacture, and marketing of controlled breathing technologies that are used for the delivery of inhaled therapeutic agents to the human lung and various lung regions. It offers AKITA, a controlled breathing device with smart card technology for the pulmonary delivery of inhaled therapeutics; and Watchhaler, an inhalation device tailored to the needs of children who need to take inhaled medication. The company also provides AKITA², a controlled breathing technology for the pulmonary delivery of inhaled therapeutics in the clinical trial setting; and LimiX, a first flow limitation valve that controls the flow rate. In addition, it offers measurement and diagnostic technologies for use in laboratory settings, including a system to measure the properties of aerosols in a minute. Further, the company provides contract development services for devices to use in clinical trials; and clinical trial logistics services. It markets its products through distributors. Activaero GmbH was founded in 2004 and is based in Gemunden, Germany. It also has locations in Munich, Germany; and Dublin, Ohio.
Complix NV is a biopharmaceutical company based in Diepenbeek, Belgium, with research facilities in Zwijnaarde, Belgium, and an office in Esch-sur-Alzette, Luxembourg. Founded in 2008, the company specializes in the discovery and development of Alphabodies, a novel class of protein therapeutics designed to target difficult disease sites, particularly in oncology and autoimmune diseases. These Alphabodies demonstrate high affinity for a variety of disease targets and possess unique stability and versatility, enabling non-injectable delivery methods. Complix aims to address challenging intracellular targets, thereby offering patients alternatives to traditional antibodies and small molecules, with the intent of improving treatment outcomes for complex conditions such as cancer, autoimmune disorders, and viral diseases.
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.
Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.
Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):
Activaero GmbH, a drug delivery company, engages in the research, development, manufacture, and marketing of controlled breathing technologies that are used for the delivery of inhaled therapeutic agents to the human lung and various lung regions. It offers AKITA, a controlled breathing device with smart card technology for the pulmonary delivery of inhaled therapeutics; and Watchhaler, an inhalation device tailored to the needs of children who need to take inhaled medication. The company also provides AKITA², a controlled breathing technology for the pulmonary delivery of inhaled therapeutics in the clinical trial setting; and LimiX, a first flow limitation valve that controls the flow rate. In addition, it offers measurement and diagnostic technologies for use in laboratory settings, including a system to measure the properties of aerosols in a minute. Further, the company provides contract development services for devices to use in clinical trials; and clinical trial logistics services. It markets its products through distributors. Activaero GmbH was founded in 2004 and is based in Gemunden, Germany. It also has locations in Munich, Germany; and Dublin, Ohio.
Apitope is a biotech company focused on the discovery and development of disease modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, Factor VIII intolerance and uveitis. The company, whose first product candidate is licensed to Merck Serono, will now progress its remaining portfolio of product candidates developed with its proprietary platform technology.
Trinean is a Belgium based technology provider, bringing micro-volume molecular spectroscopy to the next level by combining best in class analytical software with a highly standardized read-out platform. Founded in 2006 as a spin-out of the Ghent University, Belgium and Imec Leuven, Belgium, the company commercializes UV/VIS spectrometers for biomolecule quantification. The DropSense™16 and DropSense™96, analyzing up to 16 and 96 samples resp., use microfluidic chips for standardized sample analysis (DropPlates™ and Slides). The Trinean platform is complemented with a software toolbox for improved data interpretation and lab-automation.
Genomic Vision is a biotechnology company that combines pioneering Molecular Combing, a proprietary single DNA molecule detection technology, with biomarker discovery to develop and commercialize novel genetic tests and research tools for life sciences.
Genomic Vision’s products focus on DNA analysis and genetic testing in the fields of cancer, rare inherited disorders and pharmacogenomics.